trial · primary record
Group 1-Isunakinra
Triple-Negative Breast Cancer (TNBC)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2034-08 |
| Primary endpoint | Outcome-Study will test whether IL1 blockade can reduce TAM and sensitize human TNBCs to ICB. Outcome measure-changes in the TME induced by the addition of isunakinra to NAC/P will be determined. |
| Registry ID | NCT07698106 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:34.761Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07698106
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.